Hers vs LifeMD: How the Two GLP-1 Programs Differ

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

A PlexusDx Education Hub comparison of GLP-1 therapies, weight management protocols, and the genetic factors shaping every metabolic decision. Browse all Peptides & GLP-1 education.

This is an independent editorial comparison. PlexusDx has no commercial relationship with Hers or its parent company, and no affiliate links or compensation are involved. Hers and LifeMD are two of many GLP-1 telehealth options as of April 2026; this piece focuses on the two brands named in the query.

Comparing a consumer brand with a subscription clinic

Hers, part of Hims & Hers Health, is a consumer-facing telehealth brand built around a recognizable direct-to-consumer identity, while LifeMD operates as a subscription-telehealth service. Both sit in the GLP-1 weight-management category, and both keep current program structures and pricing on their own sites - see Hers's official website and LifeMD's official website.

How Hers packages GLP-1 access

A program in the Hers model typically pairs a virtual clinical evaluation with provider-issued prescriptions, dispensing either brand-name FDA-approved GLP-1 products or compounded semaglutide and tirzepatide through licensed compounding-pharmacy pathways. The consumer-brand packaging is part of the appeal, but the underlying clinical flow mirrors the rest of the category.

What that means for the patient

You still move through intake, clinician review, prescription, and follow-up. The recognizable brand and streamlined onboarding change the experience more than the pharmacology.

How LifeMD packages GLP-1 access

LifeMD's subscription structure bundles evaluation, prescribing, and follow-up under a recurring plan, with medication options and dispensing pathways that vary. As with Hers, the specifics - provider type, pharmacy partner, and billing cadence - depend on the program and should be confirmed at the source.

Where the two experiences diverge

The most visible differences between a consumer brand like Hers and a subscription clinic like LifeMD tend to be presentation and onboarding rather than the underlying prescription pathway. Hers leans on a familiar retail-style experience, while LifeMD frames its offering around an ongoing clinical relationship. For a prospective patient, that means comparing not only price but also how each program handles follow-up, dose changes, and communication with the prescribing provider over time.

Pricing you'll need to confirm at the source

Pricing across GLP-1 telehealth programs varies widely as of April 2026, with typical monthly totals spanning roughly $200 to $700-plus once program fees, medication, and compounded-pharmacy dispensing are included. Specific pricing for Hers and LifeMD lives on each brand's own site. Rather than rely on possibly-stale numbers, verify current pricing directly on each brand's pricing page before any purchase decision.

One pharmacology, many storefronts

Whichever storefront you choose, the mechanism is the same. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide) modulate appetite regulation, satiety signaling, and gastric emptying. The clinical evidence - STEP (NEJM 2021), SURMOUNT (NEJM 2022), and SURMOUNT-OSA (NEJM 2024) - reflects the compounds, and effect sizes vary by compound, dose, and population. A program's mechanism is driven by the drug, not the brand delivering it.

The genetic layer both storefronts leave out

Neither Hers nor LifeMD reads the genetics beneath a GLP-1 response. Variants in MC4R (a melanocortin receptor central to satiety), FTO, GLP1R, and TCF7L2 describe the metabolic terrain a clinician prescribes into. These pathway-level signals do not predict response to any specific compound, yet they add context a branded intake form skips. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols - Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before starting, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, the test-before-you-invest step toward an informed conversation with your provider.

Not affiliated: PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed here.

Related reading on PlexusDx: GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone, What Is GLP-1.

Frequently Asked Questions

Is Hers or LifeMD the better GLP-1 program?

Neither is objectively better; both operate in the GLP-1 telehealth space with similar clinical structures. What varies is medication options, pricing tiers, brand experience, and provider model. Individual fit depends on cost, coverage, and program mechanics, so review each brand's own details before choosing.

How do Hers and LifeMD differ on medication?

Both can prescribe GLP-1 receptor agonists through telehealth. Differences fall in the dispensing pathway (FDA-approved brand versus compounded), subscription structure, and provider type. Neither program determines the underlying pharmacology, which is driven by the compound itself rather than the storefront delivering it.

Does the Precision Peptide Genetic Test predict how I'll respond?

No. It does not predict response to any compound or telehealth program. It reports pathway-level variants in MC4R and FTO, and TCF7L2 that describe your baseline GLP-1 biology, upstream context that applies across every GLP-1 program regardless of which brand you enroll with.

How does PlexusDx compare to Hers and LifeMD?

PlexusDx pairs its Weight Management Protocols with the Precision Peptide Genetic Test for upstream genetic context. The differentiator is pathway-level insight mapping FTO, MC4R variants, context not offered at Hers, LifeMD, or most other GLP-1 telehealth programs alongside the medication itself.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.